About
Technology
Issues
FAQ
Links
Official Page
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.